Astellas Pharma has unveiled encouraging preliminary findings from its ongoing phase 4 OPTION-VMS observational study, ...

Under the terms of the deal, Biossil will receive worldwide rights to develop remetinostat, which has shown positive data in basal cell carcinoma and cutaneous T-cell lymphoma. If successfully ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell ...

Janssen-Cilag International NV, part of Johnson & Johnson, has announced encouraging results from the phase 1b/2 OrigAMI-4 ...

The National Institute for Health and Care Research (NIHR) has announced a £157 million investment over 5 years to support 10 ...

Adocia and Tonghua Dongbao have announced positive topline results from a phase 3 clinical trial of BioChaperone Lispro ...

Artificial intelligence tools that could revolutionise patient care are being trialled in phase 2 of the Medicines and ...

The partnership will see Kainos scale the Digital NHS Health Check service, allowing citizens to complete health assessments ...

Eligible patients in Scotland with relapsed or refractory multiple myeloma will now have access to a new treatment option ...